| ²é¿´: 1083 | »Ø¸´: 5 | ||
Tania.Zhang½ð³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
Ò»¸öµ¥´ÊÈçºÎ½âÊÍ
|
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Ò»¸öµ¥´Ê
ÒѾÓÐ11È˻ظ´
Ϊʲôһ¸öµ¥´ÊÓÐÄÇô¶àÒâ˼£¬ÎªÊ²Ã´¼ÇÁ˵¥´ÊÒ²²»»á·Òë
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú¡¿½âÊÍÁ½¸öÓ¢Îĵ¥´Ê clearance ºÍ tightness
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚÒ»¸öºÜ³£¼ûµÄµ¥´ÊÒâ˼¼°½âÊÍ
ÒѾÓÐ6È˻ظ´
¡¾¾Ñé¡¿Íи£±³µ¥´ÊµÄ×î¿ÆÑ§·½·¨
ÒѾÓÐ4È˻ظ´

wuzhongxin88
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 179 (¸ßÖÐÉú)
- ½ð±Ò: 3295.4
- É¢½ð: 180
- ºì»¨: 16
- Ìû×Ó: 493
- ÔÚÏß: 259.5Сʱ
- ³æºÅ: 371592
- ×¢²á: 2007-05-14
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
2Â¥2012-08-14 16:22:49
Tania.Zhang
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 18 (СѧÉú)
- ½ð±Ò: 304.5
- É¢½ð: 443
- ºì»¨: 24
- Ìû×Ó: 443
- ÔÚÏß: 101.7Сʱ
- ³æºÅ: 1313149
- ×¢²á: 2011-06-02
- ÐÔ±ð: MM
- רҵ: ÓлúºÏ³É

3Â¥2012-08-14 16:45:44
dingzitou
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 1199.5
- É¢½ð: 10
- ºì»¨: 1
- Ìû×Ó: 63
- ÔÚÏß: 35.3Сʱ
- ³æºÅ: 1726248
- ×¢²á: 2012-03-30
- ÐÔ±ð: GG
- רҵ: ºÏ³ÉÒ©Îﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
zhychen2008: ½ð±Ò+1, ¸Ðл»ØÌû½»Á÷ 2012-08-14 23:55:06
Tania.Zhang: ½ð±Ò+2, ¡ï¡ï¡ïºÜÓаïÖú 2012-08-15 08:42:55
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
zhychen2008: ½ð±Ò+1, ¸Ðл»ØÌû½»Á÷ 2012-08-14 23:55:06
Tania.Zhang: ½ð±Ò+2, ¡ï¡ï¡ïºÜÓаïÖú 2012-08-15 08:42:55
|
³£¼ûµÄҩƷרÀûÀàÐÍÈçÏ£º Component of Combination Constraining Delivery device Drug Target Formulation General interest New use Process Process (intermediate) Product Product (derivative) |
4Â¥2012-08-14 17:37:03
lhx070806
ľ³æ (Ö°Òµ×÷¼Ò)
С´ô¼Ò×åÖ®´ô´ô¾üʦ
- DRDEPI: 1
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 4366.8
- É¢½ð: 1534
- ºì»¨: 14
- ɳ·¢: 61
- Ìû×Ó: 4440
- ÔÚÏß: 992.4Сʱ
- ³æºÅ: 939574
- ×¢²á: 2010-01-09
- רҵ: ÖÐҩѧÆäËû¿ÆÑ§ÎÊÌâ

5Â¥2012-08-14 21:00:59
Tania.Zhang
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 18 (СѧÉú)
- ½ð±Ò: 304.5
- É¢½ð: 443
- ºì»¨: 24
- Ìû×Ó: 443
- ÔÚÏß: 101.7Сʱ
- ³æºÅ: 1313149
- ×¢²á: 2011-06-02
- ÐÔ±ð: MM
- רҵ: ÓлúºÏ³É

6Â¥2012-08-15 08:42:31














»Ø¸´´ËÂ¥